NCT00577720View on ClinicalTrials.gov

Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate

PHASE2CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Postmenopausal Women
Interventions
DRUG

risedronate

35mg immediate release risedronate tablet before breakfast, once a week for 13 weeks

DRUG

risedronate

35mg delayed release risedronate tablet following breakfast, once a week for 13 weeks

DRUG

risedronate

50mg delayed release risedronate tablet following breakfast, once a week for 13 weeks

DRUG

risedronate

50mg delayed release risedronate tablet before breakfast, once a week for 13 weeks

Trial Locations (6)

32608

Research Facility, Gainsville

33126

Research Facility, Miami

75247

Research Site, Dallas

78229

Research Facility, San Antonio

86813

Research Facility, Honolulu

92626

Research Facility, Costa Mesa

Sponsors

Lead Sponsor

Warner Chilcott
All Listed Sponsors
lead

Warner Chilcott

INDUSTRY

NCT00577720 - Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate | Biotech Hunter | Biotech Hunter